导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -20.58% | 4411/4773 |
| 近一周 | -3.15% | 3775/5462 |
| 近一月 | -6.08% | 3442/5421 |
| 近一季 | -3.10% | 1346/5209 |
| 近半年 | -12.02% | 3757/4920 |
| 近一年 | -30.44% | 4208/4366 |
| 近两年 | 20.43% | 2641/2954 |
| 近三年 | 5.52% | 1831/2253 |
| 成立以来 | 1.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.02% 4617/4961 |
-10.61% 4134/5312 |
- - |
- - |
| 2025 | 22.65% 1950/4813 |
22.12% 56/3635 |
-0.88% 3055/4076 |
21.49% 1782/4524 |
-16.60% 4388/4813 |
| 2024 | 18.47% 599/3463 |
-7.87% 2202/2808 |
2.74% 315/3014 |
26.81% 246/3129 |
-1.31% 1653/3463 |
| 2023 | -12.65% 1494/2656 |
-1.95% 1906/2280 |
-3.38% 785/2385 |
-4.76% 1215/2515 |
-3.20% 627/2655 |
| 2022 | -24.48% 1221/2207 |
-23.24% 1724/1919 |
12.73% 237/2016 |
-24.20% 1984/2113 |
15.13% 72/2208 |
| 2021 | -20.74% 1176/1822 |
-4.42% 862/1255 |
7.98% 652/1330 |
-14.35% 1367/1466 |
-10.35% 1602/1822 |
| 2020 | 41.32% 294/1250 |
-9.74% 717/1028 |
25.24% 159/1067 |
7.30% 790/1164 |
16.51% 163/1184 |
| 2019 | - - |
- - |
-3.28% 384/804 |
0.69% 485/850 |
8.20% 337/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实港股通新经济指数A VS. 长安沪深300非周期A(740101) |